News by subject: TRI

ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs, today announced an oral presentation at the upcoming Oligonucleotide & Peptide Therapeutics (TIDES) Conference...

Partner Therapeutics, Inc. (PTx) announced publication of a comprehensive review by Dougan et al.1 in Cancers summarizing the mechanistic rationale and pre-clinical and clinical data regarding the use of Leukine (sargramostim; glycosylated,...

On Wednesday, Interventional Pain Management Physician Raj Sureja, MD, performed the first sacroiliac (SI) joint fusion in Virginia, Maryland, and DC, using the PainTEQ LinQ SI Joint Stabilization System. https://www.painteq.com/procedure This...

What: In a proof-of-concept study, researchers at the National Institutes of Health (NIH) have developed an artificial intelligence (AI) tool that uses data from individual cells inside tumors to predict whether a person's cancer will respond to a...

A new study by surgeon-scientists at Hospital for Special Surgery (HSS) found that 25% of patients with hip impingement who underwent modern arthroscopy for their condition experienced a delay in the natural progression of osteoarthritis. The...

Researchers at Texas Biomedical Research Institute (Texas Biomed) are studying potential vaccines, antivirals and antibodies against highly pathogenic avian influenza, including H5N1 strains that closely mirror the one recently detected in cows,...

GIE Medical, a clinical stage company developing solutions for patients suffering from benign stricture(s) of the esophagus or bowel, announced today that enrollment has begun in its Paclitaxel Coated Balloon for the Treatment of Chronic Benign...

D2M...

D2M Biotherapeutics, Inc. (D2M), a clinical stage biotech company focused on developing innovative therapies in treating  Immunological-Inflammatory diseases and cancers,   today announced that the first patient had been dosed in a phase 1,...

...

?     Results from the Phase 3 SELECT-GCA study showed 46 percent of patients with giant cell arteritis (GCA) who were treated with upadacitinib (RINVOQ®; 15 mg) with a 26-week steroid taper regimen achieved sustained remission from week 12 through...

In this free webinar, review and understand the transformative impact of a biomarker-driven approach to identify sub-populations in clinical trials. Attendees will discover how artificial intelligence (AI) can expedite the analysis of clinical data...

NeuroSense Therapeutics Ltd. ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, announces the presentation of data from the Company's PARADIGM Phase 2b study of PrimeC during an Emerging Science session...

?     Next-generation non-cardiotoxic anthracycline Annamycin with notable signs of clinical efficacy in AML in combination with Cytarabine achieves preliminary CRc rate of 60% in 2nd line AML subjects in a European clinical trial ?     There are...

Renibus Therapeutics® ("Renibus"), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardio, renal and metabolic diseases, today announced an oral presentation on RBT-1 at the prestigious, invitation only,...

YS Biopharma Co., Ltd. ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and...

Two major presentations collectively representing the largest real-world data...

-- Iomab-B led bone marrow transplant produced high rates of complete remission and durable complete remission regardless of TP53 mutation status in patients age 55 and above with high-risk active relapsed or refractory acute myeloid leukemia --...

GV20 Therapeutics, a clinical stage biotechnology company integrating AI, genomics, and disease biology to create next-generation antibody therapeutics, today announced that it has entered into a clinical collaboration and supply agreement with Merck...

Calliditas Therapeutics AB ("Calliditas"), today announced additional data analyses from the 2-year Phase 3 NeflgArd trial evaluating Nefecon (TARPEYO® (budesonide) delayed-release capsules/Kinpeygo®) in patients with IgA nephropathy (IgAN), were...

Pathios Therapeutics Limited ("Pathios"), a biotech company focused on the development of first-in-class therapies for cancer,...

The European Wellness Biomedical Group (EWBG), in collaboration with the European Wellness Academy (EWA), the Baden Research Lab, and Heidelberg University, has announced substantial advances in Down Syndrome research, revealing new neuroanatomical...

Proprietary E3 ligase platform to enable protein stabilisation "at source", thereby restoring the body's sophisticated natural disease suppression processes Platform scales the assessment of E3 ligase targets while addressing the historic challenges...

TaiGen Biotechnology Company, Limited ("TaiGen") announces today that the business partner, Joincare Pharmaceutical, has completed the unblinding of influenza antiviral TG-1000 phase III study. Preliminary data shows that the median time to...

Biohaven Ltd. , a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience and oncology, today announced that it has commenced an...

Genscience LLC, a company applying genetic evidence and proprietary platforms for drug discovery and development and an affiliate of Deerfield Management Company ("Deerfield"), a healthcare investment firm, today announced a new study that shows...

Aspen Neuroscience, Inc. announced that the first patient has been dosed in the ASPIRO trial, a Phase 1/2a open label clinical trial to assess safety and tolerability of ANPD001, an autologous, dopaminergic neuron cell replacement therapy for...

Asieris Pharmaceuticals today released its 2023 Annual Report, revealing impressive outcomes achieved through its specialty pharma strategy, which has facilitated rapid progress in clinical development, early research, and commercialization. Asieris...

SalioGen Therapeutics, a biotechnology company developing next-generation genetic medicines based on its novel Gene Codingtm technology, today...

The choices made in clinical trial setup ? from patient recruitment strategies to data collection methods ? directly impact the success and...

New data demonstrates no impact of NRX-101 on gut or vaginal flora ? considered primary causes of pseudomembranous colitis due to C difficile and vaginal yeast infectionsNRX-101 previously demonstrated potent activity against resistant urinary...

In this free webinar, learn from real-world trials to understand the practical implications, benefits and challenges of eSource integration. Attendees will master the complexities of navigating site readiness by effectively engaging stakeholders and...

NeuroBo Pharmaceuticals, Inc. , a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced dosing of the first patient in the single...

Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering a novel class of small molecule medications designed to combat inflammation, today announced that David J. Bearss, Ph.D., President and CEO of Halia Therapeutics, will present...

Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced the presentation of two posters...

Allegheny Health Network's (AHN) Allegheny General Hospital (AGH) was the top U.S. enrollment site for a landmark international clinical trial comparing the performance and durability of self-expanding and balloon-expandable transcatheter aortic...

BioLineRx Ltd. , a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced a poster presentation on apheresis center efficiency and CXCR4 antagonists including APHEXDA...

Eli Lilly and Company today...

A new clinical study shows DigeSEB Sporttm, a potent sports nutrition ingredient offered by Specialty Enzymes & Probiotics, promotes protein digestion and nutrient bioavailability, a healthy gut microbiome, and the production of postbiotics, such as...

SimonMed Imaging ("SimonMed"), one of the largest outpatient medical imaging providers and radiology practices in the United States, announces the continuation of its partnership with SyntheticMR for research as well as the upcoming expansion of...

Continuous Kesimpta® treatment for up to six years showed sustained efficacy in recently diagnosed (?3 years) treatment-naïve people living with relapsing multiple sclerosis (RMS) in an analysis of the ALITHIOS open-label extension study1 Similar...

Amgen today provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIRE® (tezepelumab-ekko) in chronic obstructive pulmonary disease (COPD), which were accepted for presentation in the Clinical Trials Symposium at The American...

Community research provider EmVenio Research and Prime Healthcare, an award-winning national health system, today announce their partnership to launch the EmVenio Research Center at Prime Healthcare. The partnership allows EmVenio to conduct research...

New research in the April 2024 issue of JNCCN?Journal of the National Comprehensive Cancer Network showcases the feasibility of...

Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, presented the preclinical research findings of three potential novel drug candidates in poster format at the American Association for Cancer Research...

BOSTON, April 16, 2024 /PRNewswire/ ? Researchers from Analysis Group, a global leader in health economics and outcomes research (HEOR), have coauthored the first large-scale study that revealed racial disparities in treatment, survival, and access...

EV?Q Nano, a nanoscience company that engineers novel nanoparticles for the life, materials, and textile science industries, today announced that the American Chemical Society journal, ACS Omega, published a peer-reviewed study characterizing and...

Integral Molecular, a leader in providing safe research reagents for virology, announces the launch of its Virus Neutralization Assay Services enabling researchers to rapidly obtain high-quality data to advance their vaccines and...

Evergreen Theragnostics, Inc., a clinical-stage radiopharmaceutical company, today announced the successful completion of a $26M capital raise supported both by existing shareholders and new institutional investors, Petrichor and LIFTT. The financing...

An upcoming segment of Advancements with Ted Danson will focus on developments in research, testing, and treatments for a wide range of cancers and chronic terminal illnesses. With a look at Magnus Diagnostics Laboratories, Inc. (Magnus), audiences...